"Founded in 1974, Thomas Eye Group has served the greater Atlanta community by providing eye care services to patients ranging in age from infants to seniors. Thomas Eye Group is a full service eye care provider with offices in nine locations in and around the greater Atlanta area providing routine eye exams, glasses, contact lenses, LASIK, as well as medical, surgical and cosmetic services. Many Thomas Eye Group Atlanta physicians have undergone additional, highly specialized sub-specialty training to offer services including cataract surgery, oculoplastics, pediatrics, cornea, retina, and glaucoma."

During the past decade, Thomas Eye Group conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 7 clinical trials were completed, i.e. on average, 77.8% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 6 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Thomas Eye Group" #1 collaborator was "National Eye Institute (NEI)" with 8 trials as a collaborator, "National Institutes of Health (NIH)" with 7 trials as a collaborator, "Juvenile Diabetes Research Foundation" with 3 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator and "Allergan" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Thomas Eye Group" are "Diabetic Macular Edema" (5 trials), "Diabetic Retinopathy" (3 trials), "Epiretinal Membrane" (1 trials), "Full-thickness Macular Holes (MH)" (1 trials) and "Proliferative Diabetic Retinopathy" (1 trials). Many other conditions were trialed in "Thomas Eye Group" in a lesser frequency.

Most popular intervention types in "Thomas Eye Group" are "Drug" (7 trials), "Procedure" (5 trials), "Device" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Deferred aflibercept" (2 trials), "Deferred laser" (2 trials), "Placebo" (2 trials), "Prompt aflibercept" (2 trials) and "2-mg Intravitreous Aflibercept Injection" (1 trials). Other intervention names were less common.

The vast majority of trials in "Thomas Eye Group" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Thomas Eye Group". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Thomas Eye Group, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Thomas Eye Group, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".